Australia's Nurix Therapeutics Q4 net loss widens

Nurix Therapeutics

28/01/2026 21:13

Overview

Biopharmaceutical firm's fiscal Q4 revenue rose slightly yr/yr

Company reported a net loss for Q4, widening from the previous year

Initiated DAYBreak pivotal Phase 2 study for bexobrutideg in relapsed/refractory CLL

Outlook

Company plans Phase 3 trial for DAYBreak CLL-306 in first half of 2026

Nurix aims for Accelerated Approval submission for DAYBreak CLL-201 Phase 2 study

Company continues enrollment in NX-5948-301 Phase 1a/1b trial of bexobrutideg in patients with relapsed or refractory B cell malignancies

Result Drivers

DAYBREAK INITIATION - Nurix initiated DAYBreak pivotal Phase 2 single-arm study for bexobrutideg in relapsed/refractory CLL, supported by compelling Phase 1 data

PHASE 1 RESULTS - Bexobrutideg showed 83% objective response rate with median progression-free survival of 22.1 months and median duration of response of 20.1 months across all doses tested

IRAK4 DEGRADER - Preclinical data for IRAK4 degrader Program showed potential efficacy in autoimmune diseases, supporting further development

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$78.22 mln
Q4 Income from Operations
-$83.10 mln
Q4 Operating Expenses
$96.67 mln
Q4 Pretax Profit
-$78.22 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Nurix Therapeutics Inc is $30.00, about 54.6% above its January 27 closing price of $19.41

Press Release: ID:nGNX4HZ53X

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)